Provided by Tiger Fintech (Singapore) Pte. Ltd.

Harrow Health Inc

23.52
-0.5400-2.24%
Post-market: 23.520.00000.00%19:49 EDT
Volume:520.97K
Turnover:12.08M
Market Cap:838.59M
PE:-47.97
High:23.89
Open:23.00
Low:22.50
Close:24.06
Loading ...

Harrow Is Maintained at Buy by B. Riley Securities

Dow Jones
·
02 Apr

B. Riley Adjusts Price Target on Harrow to $65 From $69, Maintains Buy Rating

MT Newswires Live
·
01 Apr

Harrow Price Target Maintained With a $57.00/Share by HC Wainwright & Co.

Dow Jones
·
31 Mar

Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Initiatives

GuruFocus.com
·
30 Mar

Stock Track | Harrow Health Soars 5.13% Pre-Market on Strong Q4 Earnings Beat and Revenue Growth

Stock Track
·
28 Mar

Harrow (HROW) Q4 Earnings and Revenues Top Estimates

Zacks
·
28 Mar

Harrow Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
28 Mar

Harrow Inc Shares up 7.7% at $30.02 After the Bell Following Results

THOMSON REUTERS
·
28 Mar

BRIEF-Harrow Inc Reports Fourth-Quarter & Year-End 2024 Audited Financial Results

Reuters
·
28 Mar

Rpt-Harrow Health Q4 Revenue USD 66.8 Million VS. Ibes Estimate USD 61.8 Million

THOMSON REUTERS
·
28 Mar

Corrected-Harrow Inc: Q4 Core EPS $0.40 (Adds Dropped Word 'Core')

THOMSON REUTERS
·
28 Mar

Rpt-Harrow Health Q4 Core Gross Margin 84%

THOMSON REUTERS
·
28 Mar

Harrow Q4 2024 Adj. EPS $0.40 Beats $0.07 Estimate, Sales $66.800M Beat $61.790M Estimate

Benzinga
·
28 Mar

Harrow Inc: Q4 EPS $0.40

THOMSON REUTERS
·
28 Mar

Harrow Health Q4 Core Gross Margin 84%

THOMSON REUTERS
·
28 Mar

Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results

Business Wire
·
28 Mar

Press Release: Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025

Dow Jones
·
27 Mar

Stock Track | Harrow Health Soars Nearly 6% Pre-Market on CMS Approval for Triesence Reimbursement

Stock Track
·
24 Mar

Stock Track | Harrow Health Soars 5.95% as CMS Approves Transitional Pass-Through Status for Triesence

Stock Track
·
24 Mar

Harrow Inc - CMS Approves Transitional Pass-Through Status for Harrow's Triesence 40 Mg/Ml

THOMSON REUTERS
·
24 Mar